A prospective trial to evaluate the clinical efficacy and safety of neoadjuvant chemotherapy with arsenic trioxide and carboplatin in locally advanced cervical cancer: a study protocol for randomized controlled clinical trial

Ze Yang He*†, Hai Ying Li†, Jiao Yan, Si Jin Li, Dao Cheng Li and Zhong Zhe Liang

Abstract

Background: Cervical cancer is the fourth most common malignancy in women, which is threatening female reproductive tract health. Chemotherapy can be used for neoadjuvant therapy of locally advanced cervical cancer and postoperative adjuvant therapy for patients with high-risk factors, so as to reduce the focus, sensitize radiotherapy, and reduce recurrence. The current first-line treatment is paclitaxel combined with platinum. Many literature studies have found that As2O3 alone or in combination with platinum drugs have good efficacy in a variety of tumors both in vivo and in vitro. Moreover, our research group has verified that the efficacy of As2O3 combined with platinum drugs in the treatment of cervical cancer is not inferior to the traditional first-line regimen at the cellular and animal levels, and paclitaxel is more expensive than As2O3. Hence, we aim to evaluate the clinical efficacy and safety of neoadjuvant chemotherapy with As2O3 and carboplatin in locally advanced cervical cancer.

Methods: Sixty participants in the IB2, IIA2, and IIB stages of cervical cancer will be recruited in this study. After excluding patients who did not meet the criteria, they were randomly assigned to two groups in a 1:1 ratio. All patients underwent colposcopic biopsies to confirm the diagnosis and detailed clinical examinations. Eligible patients will receive either 2 cycles of paclitaxel and carboplatin or As2O3 and carboplatin every 3 weeks. Patients were assessed for clinical efficacy after the second cycle of chemotherapy. Patients who had disease stable or disease progression at these time points will receive concurrent chemotherapy and radiation directly, while responders will receive PiverRutledge grade III radical hysterectomy and bilateral pelvic lymphadenectomy. Both groups of patients undergoing radical hysterectomy were given adjuvant therapy as per protocol-defined criteria. The efficacy and toxicity of the two groups were evaluated according to WHO acute and subacute toxicity classification standards.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Up to now, it is estimated that there are 19.3 million new cases and 10 million cancer deaths in the world, and half of the cancer cases and cancer deaths occur in Asia. Among them, 604,127 new cases and 341,831 deaths occur in cervical cancer, ninth among 36 types of cancer and fourth among female malignant tumors [1].

According to the International Union of Obstetrics and Gynecology (FIGO) 2009 staging, the standard treatment for patients with locally advanced cervical cancer, namely stage IB2–IVA, is platinum-based concurrent chemotherapy and radiotherapy [2, 3].

Chemotherapy plays an important role in locally advanced cervical cancer and can be used for neoadjuvant therapy of locally advanced cervical cancer and postoperative adjuvant therapy of patients with high-risk factors, so as to achieve the purpose of shrinking lesions, sensitizing radiotherapy, reducing recurrence, and so on. Neoadjuvant chemotherapy is to reduce tumor volume and kills small lesions through chemotherapy; facilitates subsequent surgery, radiotherapy, and other treatments; and brings new possibilities for patients with locally advanced cervical cancer. Many past studies have found that surgical or radiotherapy after neoadjuvant chemotherapy seems to have better survival outcomes than direct chemoradiotherapy [4–7]. However, it has recently been found that compared with direct chemoradiotherapy, radiotherapy after neoadjuvant chemotherapy is less effective and more prone to some toxic and side reactions [8]. A phase III clinical trial from a single center found that platinum-based concurrent chemoradiotherapy for locally advanced cervical cancer achieved better DFS than radical surgery after neoadjuvant chemotherapy, and OS was comparable [9]. So, neoadjuvant chemotherapy plus surgery is still very controversial and lacks sufficient evidence.

Arsenic trioxide (As$_2$O$_3$) is one of the active components of traditional Chinese medicine arsenic. Since the 1970s, Chinese experts have applied it to patients with acute promyelocytic leukemia (APL) and found that its remission rate reaches about 80%, and its toxic side effects such as bone marrow suppression are small, so it has been recognized and widely used worldwide. In 2001, it was approved by the American Food and Drug Administration (FDA) for the treatment of APL by fast track [10]. Later studies at home and abroad have found that As$_2$O$_3$ has a complex and extensive tumor inhibition mechanism, and its therapeutic effect has been extended to breast cancer [11], lung cancer [12, 13], gastric cancer [14, 15], liver cancer [16, 17], bladder cancer [18], cervical cancer [19], and other solid tumors. In the field of cervical cancer research, the tumor inhibition mechanism of As$_2$O$_3$ mainly focuses on the following aspects: (1) affect the proliferation and apoptosis of cervical cancer cells (interfere with the tumor cell cycle, affect the expression of genes related to proliferation and apoptosis, and affect the intracellular structure and function); (2) prevent the formation of tumor blood vessels and the invasion and metastasis of cervical cancer cells; (3) enhanced radiosensitivity; and (4) tumor immunosuppression was downregulated [20–26].

Based on a large number of the previous cell and animal experiments and clinical data on the combined use of As$_2$O$_3$ and carboplatin, this study is the first to use As$_2$O$_3$ combined with carboplatin in patients with cervical cancer, which has good operability and safety, and to explore an effective, safe, and economic drug for cervical cancer.

Materials and methods
Objective
The primary objective of this study is to evaluate the efficacy of the As$_2$O$_3$ plus carboplatin regimen as neoadjuvant chemotherapy for cervical cancer. The secondary objective of this study is to evaluate the safety of the As$_2$O$_3$ plus carboplatin regimen as neoadjuvant chemotherapy for cervix cancer.

Study design
This trial is a single-center, non-inferiority, controlled, randomized, prospective study. The study started in January 2019 and is still ongoing. We recruited histopathologically confirmed patients with IB2–IIB stage cervical cancer without distant metastasis from the First Affiliated Hospital of Guangzhou University of Chinese Medicine according to the cervical cancer FIGO staging (2009). Patients with cervical cancer will be randomly allocated to either the experimental group or the control group, then they will be administrated As$_2$O$_3$ plus carboplatin.
or paclitaxel plus carboplatin for two cycles, which may last up to 6 weeks. Participants will be followed until surgery or drop out of the study. An overview of the study is shown in Fig. 1. The Standard Protocol Items: Interven-tional Trial Recommendations (SPIRIT) Checklist is used to detail the study protocol [27] (see Table 1). Two supervisors will monitor the accuracy and feasibility of the process. The institutional ethics review board approved the study protocol.

Inclusion criteria
Participants must meet the following inclusive criteria: (1) age 20–60; (2) histopathologically proven stage IB2, IIA2, IIB cervical carcinoma without therapy; (3) the Karnofsky Functional Status Score should be at least 70; (4) blood test and liver and kidney function were normal before treatment; (5) there was no evidence of distant metastasis; and (6) no serious heart, liver, kidney, blood system, and other important organ diseases.

Exclusion criteria
Exclusion criteria are as follows: (1) there is recurrence or distant metastasis; (2) prior radiotherapy, chemotherapy, immunotherapy, or surgery; (3) serious comorbidities, pregnancy, or lactation; (4) allergic to arsenic and participated in other clinical trials in the past 3 months; and (5) the condition is too late to receive surgery combined with adjuvant chemotherapy.

Setting and participants

**Participant recruitment and screening**

The recruitment process of subjects will be publicized by following the WeChat official public account at the Gynecology Department of the First Affiliated Hospital of Guangzhou University of Chinese Medicine, and in cooperation with the Oncology Department of our hospital, cervical cancer patients with surgical indications will be transferred to the cervical cancer research team, and our department experts with oncology background will be screened. Qualified candidates will be invited to participate in the study.
participate in the selection process. All patients underwent colposcopic biopsies to confirm the diagnosis and detailed clinical examinations, including pelvic examinations by two clinicians to determine the initial stage. Patients also received blood tests, color ultrasound of computed tomography, or magnetic resonance imaging of the abdomen and pelvis before being randomly assigned.

**Study protocol**

Eligible patients will receive either 2 cycles of paclitaxel (135–175 mg/m², day 1) and carboplatin (dose 5 to 6 zones below the curve, day 1) or As₂O₃ (8 mg/m², days 1 to 7) and carboplatin (dose 5 to 6 zones below the curve, day 1) every 3 weeks. Patients were assessed for clinical efficacy after the second cycle of chemotherapy. Patients who had disease stable or disease progression at these time points will receive concurrent chemotherapy and radiation directly, while responders will receive Piver-Rutledge grade III radical hysterectomy, bilateral pelvic lymphadenectomy, and, if necessary, paraaortic subaortic lymph node sampling by a specialist gynecologic oncologist 3 weeks after the second cycle of chemotherapy.

**Follow-up treatment**

According to the NCCN guidelines, both groups of patients undergoing radical hysterectomy were given adjuvant therapy (radiotherapy or concurrent chemotherapy and radiotherapy) as per protocol defined [28]. According to the histopathological evaluation of surgical specimens, adjuvant chemoradiotherapy was given in the case of positive surgical margin, lymph node metastasis, or parametrium involvement. Based on any two of the following characteristics: deep cervical interstitial invasion, tumor size > 4 cm, or lymphatic vascular invasion, adjuvant radiotherapy was given alone. The efficacy and toxicity of the two groups were evaluated according to WHO acute and subacute toxicity classification standards (RECIST).

**Randomization and blinding**

Qualified patients were randomly assigned to either study group in a 1:1 ratio using a random number table. Treatment assignments were uncovered as follows: Once informed consent was obtained from eligible patients, the numbered, opaque, sealed envelopes containing
treatment details were opened by the investigators, and patients were assigned corresponding interventions.

**Sample size**
The main aim of this research was to study the efficacy of neoadjuvant chemotherapy for cervical cancer and to use this as the basis for sample size calculation. Based on a related large cohort study [5], the effective rate in patients with locally advanced cervical cancer was approximately 67%. The G-power (V.3.1) formula was used to calculate the sample size difference between the two independent ratios in non-inferiority trials. Power calculations assumed 1:1 randomization, a two-sided test with a type I error rate (α) of 0.05, and a type II error rate (1−β) of 0.8. The non-inferiority margin for the primary outcome was set at 0.9 by the trial clinicians and statisticians. We want 25 participants per queue. Considering the 20% loss-to-follow-up rate, the sample size should be 30 per cohort and 60 overall.

**Outcome**
An investigator will be put in charge of the following up weekly by telephone or outpatient.

**Primary outcome**
The study’s primary outcome is the effective rate of NACT, that is to say, how much the tumor shrinks after curative treatment. At the end of the study, this indicator will be calculated by the response evaluation criteria in solid tumors [29] (RECIST) The results in the assessment of tumor size will be obtained by computed tomography or magnetic resonance imaging. Results assessment of tumor markers will be obtained by blood drawn. Unless follow-up is lost, the date of the last assessment will be recorded after two cycles of the NACT.

**Secondary outcomes**
The secondary outcome of this study is the safety of NACT, which is evaluated by adverse events (AE) and adverse drug reactions (ADR). AE refers to adverse medical events that occur after patients or clinical trial subjects receive a drug, but they do not necessarily have a causal relationship with the treatment. ADR refers to the harmful, but not expected, causal reaction that occurs during the normal application of the drug at the prescribed dose. To elucidate AE and ADR, we will evaluate the following secondary outcomes: blood analysis, coagulation function, hepatic and renal function, and gastrointestinal adverse events. The toxic effects of patients during chemotherapy were defined accordingly to NCI-CTCAE (v. 4.03) of grade 3 and above [30]. The clinical research will develop a corresponding data security monitoring plan based on the level of risk. All adverse events are recorded in detail, properly handled, and tracked until they are properly resolved or the condition is stable, and report serious adverse events and unexpected events to the ethics committee, competent authorities, sponsors, and drug regulatory authorities promptly under regulations; the main investigator regularly checks all adverse events, which shall be reviewed cumulatively, and researchers’ meetings shall be held when necessary to evaluate the risks and benefits of the research; researches with greater than the minimum risk will be arranged with independent data monitors to monitor the research data, and high-risk research will establish independent data to ensure security, and the Supervisory Committee monitors the accumulated safety data and effectiveness data to make recommendations on whether the study should continue.

**Statistical analysis**
Statistical analysis will be conducted using the SPSS software V.24.0 (SPSS Inc., Chicago, IL, USA). The $\chi^2$ test will be used for counting the data of the two groups. Measurement data will be expressed as mean ± standard deviation (\(\bar{x} \pm s\)), and a $T$-test will be used, too. $P$-value < 0.05 means the difference is statistically significant.

**Discussion**
Stage IB2–IVA cervical cancer is treated with chemoradiotherapy, surgery, or both. However, if the tumor is too large or too deep, or too wide, it will add difficulty to the surgical treatment. Chemotherapy alone can eliminate many small lesions but has relatively little effect on large masses, and radical radiotherapy, including external beam radiation and endoluminal therapy, can provide a good chance of being cured, but the maximum radiation dose given to patients is limited by the tolerance of normal tissues giving, especially adjacent tissues that are prone to radiation proctitis, radiation bladder side effects such as inflammation, greatly reduce the quality of life of patients, and the cost of radiotherapy is expensive. If the small metastatic lesions are controlled by chemotherapy first and the tumor size is reduced, the chance of surgery can be greatly increased, even the difficulty of surgery can be reduced, and the burden of adjuvant therapy can be reduced. Therefore, neoadjuvant chemotherapy seems to be able to ensure both effectiveness and achieve certain economic effects.

As$_2$O$_3$ is now commonly used in the treatment of acute promyelocytic leukemia, and its low cost, side effects, and a wide range of anti-tumor effects. The best example of its application in other solid tumors is liver cancer, which has shown good efficacy in both single and combination drugs, in vivo and in vitro, and even in clinical trials. Therefore, in 2004, China’s Food and Drug
Administration approved As₂O₃ for advanced liver cancer [31]. There have been many studies trying to combine As₂O₃ with platinum and other first-line chemotherapy regimens to observe its efficacy increases in various solid tumors, and whether patients tolerate side effects: there are reports of As₂O₃ combined with ICE regimen (ifosfamide + cisplatin + etoposide) in the treatment of relapsed and refractory non-Hodgkin's lymphoma with a clinical total effective rate 60%. The main adverse reactions were bone marrow suppression, and leukopenia of grade III~IV was 12/15 (80.0%). However, patients can tolerate it, so the efficacy is good and side effects can be tolerated, which is worthy of clinical promotion [32]. Compared with cisplatin alone, As₂O₃ combined with intracavitary injection in the treatment of malignant pleural effusion has increased efficacy and similar adverse reactions, which can be tolerated by patients [33]. Reviewing the cases of extremity osteosarcoma lung metastases in the Bone and Soft Tissue Tumor Center of Peking University People’s Hospital for more than 10 years, it was found that As₂O₃ combined with first-line chemotherapy (doxorubicin, cisplatin, high-dose methotrexate, and ifosfamide) may be an effective and tolerant new treatment option [34]. As₂O₃ combined with cisplatin showed good efficacy in the treatment of advanced gallbladder cancer, with few adverse reactions, mainly digestive tract reactions, mild bone marrow suppression, and liver function impairment [35]. How about applying it to cervical cancer? In animal experiments, the combined use of As₂O₃ and cisplatin increased the efficacy of the single drug on the transplanted tumor of cervical cancer in nude mice, and the examination of blood and the dissection of liver and kidney organs in nude mice showed no increase in bone marrow suppression, liver and kidney injury, and other toxic and side effects [36]. In addition, it has been reported that As₂O₃ has been used in the clinical application of cervical cancer. When As₂O₃ is used in patients with cervical cancer radiotherapy, it is found that its sensitization effect on cervical cancer radiotherapy is similar to that of cisplatin, but its side effects are smaller [37]. Therefore, what about combining As₂O₃ with platinum drugs for neoadjuvant chemotherapy? And can it be non-inferior to the standard first-line chemotherapy regimen of paclitaxel combined with platinum?

Of course, our study also has some limitations. Firstly, only patients with stages IB2, IIA2, and IIB were included. To be able to give full play to maximum advantages of the neoadjuvant chemotherapy combined surgery, cases of stage III and IVA surgery may be more difficult to operate on. Owing to the small lesion of stage IIA1, direct chemoradiotherapy or direct postoperative adjuvant therapy is more effective, while for stages IB2, IIA2, and IIB, due to the large size of the tumor, direct surgery may be more difficult, and direct radiotherapy can greatly stimulate adjacent organs on account of the dose. At this time, neoadjuvant chemotherapy combined with surgery can be used to achieve ideal results. Secondly, as this study was a single-center study with limited staging, it was relatively difficult to collect cases and the number of cases was greatly reduced. Therefore, under the condition of minimizing bias, the number of cases included in this study was small, but if the results are ideal, the study scale can be expanded. Thirdly, because the As₂O₃ solution needs to be used continuously for 8 days, while the other one needs only one day, double-blind method could not be realized in this study, which may bring some selective bias.

This proposal is mainly to observe the efficacy and safety of arsenic trioxide combined with platinum drugs in neoadjuvant chemotherapy. The results of this study will provide a new possibility for the treatment options for cervical cancer.

**Trial status**
Participant recruitment started in January 2019 and is still ongoing.

**Abbreviations**
AS₂O₃/ATO: Arsenic trioxide; FIGO: International Union of Obstetrics and Gynecology; APL: Acute promyelocytic leukemia; FDA: Food and Drug Administration; RECIST: Response Evaluation Criteria in Solid Tumors; NACT: Neoadjuvant chemotherapy; AE: Adverse events; ADR: Adverse drug reaction; CTCAE: Common Terminology Criteria for Adverse Events; ICE: Ifosfamide + cisplatin + etoposide.

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1186/s13063-022-06489-1.

**Acknowledgements**
We would like to acknowledge all the participants and members who will participate in this study as well as the First Affiliated Hospital of Guangzhou University of Chinese Medicine for their support.

**Authors’ contributions**
LSJ and LZZ participated in the design and review of the final version of the paper; while HZY and LHY were responsible for drafting the manuscript and data collection and analysis of participants. YJ edited the final manuscript. LSJ and LDC will oversee the progress and data analysis of the entire study. All authors participated in the design and writing of the study. All approved and agreed to submit the final version of the manuscript.

**Funding**
This work is subsidized by the Administration of Traditional Chinese Medicine, Guangdong, China.
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, cervical cancer, version 1.2021—Oct 2, 2020. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf.
3. Gadducci A, Cosio S. Neoadjuvant chemotherapy in locally advanced cervical cancer: review of the literature and perspectives of clinical research. Anticancer Res. 2020;40(9):4819–28.
4. Neoadjuvant Chemotherapy for Cervical Cancer Meta-Analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol. 2002;20(1):179–88.
5. Benedetti-Panici P, Greggi S, Colombo A, Amoroso M, Smaniotto D, Gianarelli D, et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results of the Italian multicenter randomized study. J Clin Oncol. 2002;20(1):179–88.
6. Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-Analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer. 2009;45(2):228–47.
7. Sardi JE, Sananes CE, Giaroli A, et al. Neoadjuvant chemotherapy in cervical carcinoma stage IB: a randomized controlled trial. Int J Gynecol Cancer. 1998;8:441–50.
8. da Costa SCS, Bonadio RC, Gabrielli FCC, Aranha AS, Dias Genta MLN, Miranda VC, et al. Neoadjuvant chemotherapy with cisplatin and gemcitabine followed by chemoradiation versus chemoradiation for locally advanced cervical cancer: a randomised phase II trial. J Clin Oncol. 2019;37(33):3124–31.
9. Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri Chopra S, et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol. 2018;36(16):1548–55.
10. Altrmant KH. Introduction: the history of arsenic trioxide in cancer therapy [J]. Oncologist. 2001;Suppl2(Suppl2):1.
11. Shi Y, Cao T, Huang H. Arsenic trioxide inhibits cell growth and motility via up-regulation of let-7a in breast cancer cells. Cell Cycle. 2017;16(24):2396–403.
12. Gu SY, Chen HY, Dai HM. mir-155/BACH1 signaling pathway in human lung adenocarcinoma cell death induced by arsenic trioxide. Sichuan Daxue Xuebao Yi Xue Ban. 2017;48(6):828–33.
13. Jiang X, Chen C, Gu S. Regulation of ABCG2 by nuclear factor kappa B affects the sensitivity of human lung adenocarcinoma A549 cells to arsenic trioxide. Environ Toxicol Pharmacol. 2017;57(1):141–50.
14. Abudoureyimu A, Muhermitabke A. Arsenic trioxide regulates gastric cancer cell apoptosis by mediating cAMP. Eur Rev Med Pharmacol Sci. 2017;21:612–7.
15. Sun XP, Zhang X, He C, Qiao H, Jiang X, Jiang H, et al. ABT-737 synergizes with arsenic trioxide to induce apoptosis of gastric carcinoma cells in vitro and in vivo. J Int Med Res. 2012;40:1251–64.
16. Shao HB, Xu K, Su H, et al. Clinical study of lipiodol-arsenic trioxide emulsion in the treatment of primary hepatic carcinoma by interventional ways. J Oncology. 2004;06:638–40.
17. Duqo EB, Yedjou CG, Stevens JJ. Therapeutic potential of arsenic trioxide (ATO) in treatment of hepatocellular carcinoma: role of oxidative stress in ATO-induced apoptosis. Ann Clin Pathol. 2017;5(1):1101.
18. Indira J, Gayathri C, Sandeep S. Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. Exp Cell Res. 2010;316(1):2174–88.
19. Um SJ, Lee SY, Kim EJ. Down-regulation of human papillomavirus E6/E7 oncogene by arsenic trioxide in cervical carcinoma cells. Cancer Lett. 2002;181(1):11–22.
20. Wang H, Gao P, Zheng J. Arsenic trioxide inhibits cell proliferation and human papillomavirus oncoprotein expression in cervical cancer cells. Biochem Biophys Res Commun. 2014;451(4):556–61.
21. Kang YH, Lee SJ. Role of p38 MAPK and JNK in enhanced cervical cancer cell killing by the combination of arsenic trioxide and ionizing radiation. Oncol Rep. 2008;20(3):637–43.
22. Zhou J, Ye J, Zhao X, et al. JWA is required for arsenic trioxide induced apoptosis in Hela and MCF-7 cells via reactive oxygen species and mitochondria linked signal pathway [J]. Toxicol Appl Pharmacol. 2008;230(1):33–40.
23. Xu B, Wang J, Ban DH, et al. Arsenic trioxide induces apoptosis and mechanism of cervical cancer cell line in vitro. J Appl Med. 2006;23(4):25–7.
24. Ma XB, Gu ZY, Song HJ, et al. Effects of arsenic trioxide on HTERT-mRNA expression and telomerase activity in Hela cells. J Mil Med Coll. 2004;25(1):26–8.
25. Lin C, La L, Su Z, Shi YH. Effect and mechanism of arsenic trioxide on xenograft of cervical carcinoma in nude mice. Cancer Res. 2011;71(39):369–72.
26. He CY, Ni R, Liao A. Effect of arsenic trioxide on immunosuppression of Hela cells in cervical carcinoma. J Mod Integr Tradit West Med. 2011;20(20):2480–1,2484.
27. Chan A-W, Zetland JM, Gatzche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7386.
28. Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical cancer with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006;65:169–76.
29. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.45.
30. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Washington, DC: US Department of Health and Human Services; 2010. https://www.ecore.org/services/doc/ctca/CTCAE_4_0_3_2010_06_14_Quick Reference_5x7.pdf.
31. Qu FL, Hao XZ. A Phase II multicenter clinical study of arsenic trioxide in the treatment of primary liver cancer. Chinese J Oncol. 2011;09:697–701.
32. Cao HW, Zhao XH, Zhao XH. clinical observation of arsenic trioxide combined with ICE regimen in the treatment of relapsed refractory non-Hodgkin lymphoma. Hainan Med. 2016;1:111–3.
33. Yang XM, Chen YH, Chen YH, et al. Clinical study of arsenic trioxide combined with cisplatin in the treatment of malignant pleural effusion. West China Med. 2013;35:707–9.
34. Zheng ZH, Wang XH, Wang XJ. The efficacy of first-line chemotherapy combined with arsenic trioxide in the treatment of metastatic osteosarcoma of the extremities. Chin J Oncol. 2017;10:502–7.
35. Liu YJ, Song WX, Gao F, et al. Efficacy of arsenic trioxide combined with chemotherapy in the treatment of advanced gallbladder cancer. Zhejiang Clin Med. 2015;6:901–3.
36. Zhou XI, Chen ZD. Effect and mechanism of different doses of arsenic trioxide alone and combined cisplatin on human cervical cancer transplanted tumor. Chin Med Sci. 2015;5(1):44–7.

37. Pan DF, Huang L. Arsenic trioxide enhances radiosensitization of cervical cancer in vitro. J Clin Microbiol. 2013;6:473–5.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.